Menapharm is focused on markets generally perceived to be of higher risk, but with great potential reward. Risk is relative, and is significantly reduced by the experience Menapharm brings to its partners.

The global pharmaceutical market is expected to expand from roughly USD 1.7–1.8 trillion in 2025 to about USD 2.3–2.4 trillion by 2030, reflecting an average compound annual growth rate (CAGR) between 6% and 7% during that period.

The Middle East & Africa pharmaceuticals market is projected to rise from USD 30.1 billion in 2024 to USD 42.4 billion by 2030, at a 6.1% CAGR